|
 |
| home > ebr > autumn 2003 > osteoporosis - a field posing challenges and rewards |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| With more than 50 million women affected in Western countries, osteoporosis is a major worldwide health issue of the 21st Century. This market will also be one of the fastest growing of the industry - revenues, currently over €5 billion are forecasted to hit €11 billion by 2010, notwithstanding significant clinical unmet needs and considerable commercial potential. Despite effective therapies, osteoporosis remains a major clinical problem, many patients cannot or will not take available therapies or do not respond to treatment. For this reason research continues for more effective and better tolerated agents. The anti-resorptive segment, although already well-served, is the most active with many compounds in clinical and pre-clinical development, followed by new modulators of the oestrogen and the androgen receptors. However, anabolic agents represent the most important advance in the therapy of osteoporosis and their potential may be substantially greater than the anti-resorptives. Recently, genomics and genetics have provided significant insights into the understanding of major bone anabolic pathways, such as BMP and LRP5, and in the identification of innovative and hopefully druggable targets. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Enrico Bastianelli, Vice-President of Corporate Development and Philippe Ballero, Chief Executive Officer at ProSkelia Pharmaceuticals
Enrico Bastianelli's career in the pharmaceutical industry started with Procter & Gamble Pharmaceuticals in 1996 and Abbott Laboratories as Product Manager. In 1999 he joined the strategic consulting group McKinsey & Co, working in Europe for major pharmaceutical and smaller biotech companies. In 2001 he joined UCB in Belgium as Global Licensing Manager and in 2002 moved to ProSkelia as Vice President of Corporate Development. Dr Bastianelli obtained his PhD in Medicine, Surgery and Obstetrics at the Free University of Brussels, Belgium, followed by a degree in Business Management at the Institut d'Aministration et de Gestion, Catholic University of Louvain in Belgium. Dr Bastianelli has authored 20 scientific papers and has co-authored a number of business and scientific reports.
Philippe Ballero MBA is Chief Executive Officer at Proskelia. Prior to joining ProSkelia he was CEO of Tibotec-Virco, the Belgian biotech company acquired by Johnson & Johnson in April 2002, and President of Yamanouchi Europe.
His extensive industry experience covers companies such as Schering-Plough, Abbott Diagnostics where he headed up the Scandinavian operations, and Johnson & Johnson Cilag where he was Managing Director of the export operations. Mr Ballero holds an MBA from New York University.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
